SPARC Endogenous Level, rather than Fibroblast-Produced SPARC or Stroma Reorganization Induced by SPARC, Is Responsible for Melanoma Cell Growth  by Prada, Federico et al.
SPARC Endogenous Level, rather than Fibroblast-
Produced SPARC or Stroma Reorganization Induced
by SPARC, Is Responsible for Melanoma Cell Growth
Federico Prada1, Lorena G. Benedetti1, Alicia I. Bravo2, Mariano J. Alvarez1,4, Cecilia Carbone3 and
Osvaldo L. Podhajcer1
SPARC (secreted protein acidic and rich in cysteine) is a matricellular protein whose overexpression in
malignant or tumor-stromal cells is often associated with increased aggressiveness and bad prognosis in a wide
range of human cancer types, particularly melanoma. We established the impact that changes in the level of
SPARC produced by malignant cells and neighboring stromal cells have on melanoma growth. Melanoma cell
growth in monolayer was only slightly affected by changes in SPARC levels. However, melanoma growth in
spheroids was strongly inhibited upon SPARC hyperexpression and conversely enhanced when SPARC
expression was downregulated. Interestingly, SPARC overexpression in neighboring fibroblasts had no effect on
spheroid growth irrespective of SPARC levels expressed by the melanoma cells, themselves. Downregulation of
SPARC expression in melanoma cells induced their rejection in vivo through a mechanism mediated exclusively
by host polymorphonuclear cells. On the other hand, SPARC hyperexpression enhanced vascular density,
collagen deposition, and fibroblast recruitment in the surrounding stroma without affecting melanoma growth.
In agreement with the in vitro data, overexpression of SPARC in co-injected fibroblasts did not affect melanoma
growth in vivo. All the data indicate that melanoma growth is not subject to regulation by exogenous SPARC,
nor by stromal organization, but only by SPARC levels produced by the malignant cells themselves.
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INTRODUCTION
Cancer progression is the result of a dynamic interaction
between malignant cells, neighboring stromal cells such as
fibroblasts and endothelial cells, and the host’s immune cells
that infiltrate the tumor mass. It is increasingly clear that
proteins secreted by the tumor cells or surrounding stromal
cells that become structural or transient components of the
extracellular matrix (ECM) might play a significant role in
cell–ECM interactions, helping the tumor cell to invade the
neighboring stroma and disseminate (Murphy-Ullrich, 2001).
One of the transient components of the ECM is the
matricellular protein SPARC (secreted protein acidic and rich
in cysteine). SPARC is a secreted glycoprotein associated with
cell–matrix interactions during tissue remodeling, morpho-
genesis, migration, and proliferation (Bradshaw et al., 2001).
SPARC is produced by different cell types, including
endothelial cells, and was found to bind specific growth
factors, such as vascular endothelial growth factor, platelet-
derived growth factor, and basic fibroblast growth factor, or
interact with their signaling pathways, suggesting that it might
play a role in vasculogenesis (Yan and Sage, 1999). SPARC
was also found to regulate matrix metalloproteinase expres-
sion and activity in normal and malignant cells, suggesting a
role in enhanced tumor aggressiveness (Lane and Sage, 1994;
Ledda et al., 1997b; Yan and Sage, 1999).
Several studies including expression array analysis indi-
cate that SPARC overexpression is associated with increased
aggressiveness of various human cancers (Framson and Sage,
2004, and references herein). In several adenocarcinomas,
SPARC is faintly or not at all expressed in the malignant cells;
however, its expression in stromal fibroblasts of human lung
and colon carcinoma correlates with poor prognosis (Kou-
kourakis et al., 2003; Porte et al., 1995). It has been proposed
that SPARC’s capacity to induce cell disengagement from the
ECM favors cell migration and dissemination (Ledda et al.,
1997a; Rempel et al., 2001). Indeed, SPARC was found to
enhance the migration and invasive capacity of melanoma
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and glioblastoma cells (Golembieski et al., 1999; Ledda et al.,
1997a; Rempel et al., 2001, 1998). In addition, SPARC
increased the migration of prostate cancer cells toward bone
extracts, highlighting its potential role as a chemotactic factor
in bone metastasis (Thomas et al., 2000). More recently,
SPARC was identified as one of the selected proteins that
confer lung metastatic capacity to breast cancer cells (Minn
et al., 2005). Moreover, SPARC was found to modulate the
capacity of PMNs to eliminate melanoma cells in vitro
(Alvarez et al., 2005).
Contrary to previous evidence, SPARC expression was
associated with good prognosis in human neuroblastoma
through the inhibition of angiogenesis (Yang et al., 2004).
Moreover, SPARC-null mice exhibited enhanced peritoneal
dissemination of ovarian cancer cells (Said and Motamed,
2005). SPARC also inhibited the in vitro growth of some
human pancreatic cancer cell lines (Sato et al., 2003;
Puolakkainen et al., 2004). Furthermore, SPARC’s effect on
breast cancer growth also appears controversial because
recent data demonstrated that its ectopic expression in
MDA-MB231 cells inhibited cell capacity to metastasize to
different organs, including bone and lungs (Koblinski et al.,
2005). In addition, reexpression of SPARC in colon cancer
cells rendered the tumor more susceptible to proapoptotic
chemotherapeutic molecules, suggesting that reduced levels of
SPARC might promote apoptosis resistance (Tai et al., 2005).
This controversial evidence might indicate that SPARC’s
effect in cancer could be strongly dependent on the tumor
cell type. Because SPARC is produced not only by the
malignant cells but also by neighboring fibroblasts and
endothelial cells, it is unclear whether the protein produced
by the different cell components of a tumor mass might have
different roles in tumor growth. In fact, recent attempts to
elucidate the role of host-derived SPARC using SPARC-null
mice led to opposite results; one group claimed enhanced
tumor growth (Brekken et al., 2003), whereas others showed
impaired tumor growth in SPARC-null mice (Sangaletti et al.,
2003). Despite this discrepancy both groups claimed that the
major role of SPARC is associated with the assembly and
function of the ECM.
In an attempt to understand the role of SPARC in
melanoma, we modulated SPARC expression in malignant
melanoma cells and in neighboring fibroblasts by over-
expressing or downregulating SPARC levels through adeno-
viral gene transfer. The effects of SPARC were assessed
in vitro, using both melanoma cell monolayers and spheroids
made of melanoma cells alone or combined with stromal
cells, and in vivo following xenograft transplantation of
melanoma cells alone or combined with stromal cells. We
observed that the modulation of SPARC levels only in
melanoma cells, and not in the neighboring stromal cells,
affected melanoma cell growth.
RESULTS
Positive and negative modulation of SPARC levels does not
profoundly affect melanoma cell growth in vitro
The human SPARC sense and antisense full-length cDNAs
were cloned into an E1/E3-deleted recombinant adenoviral
vector (Ad-SP and Ad-SPas, respectively) containing a Rous
sarcoma virus (RSV) promoter driving gene transcription.
Using 5108 50% tissue culture infectious doses (TCID50)/
ml as the viral dose, 60–80% of melanoma cells, depending
on the cell line, were transduced as assessed with Ad-bgal
(data not shown). Conditioned media obtained from A375N
and IIB-Mel-J melanoma cells transduced with 5108
TCID50/ml Ad-SPas showed an important decrease in SPARC
levels compared both to mock- and to Ad-bgal-transduced
melanoma cells (Figure 1a). Unexpectedly, transduction of
melanoma cells with Ad-bgal led to increased SPARC
expression (Figure 1a). This increase was independent of
the transgene because it was also observed with an
adenoviral vector carrying CRE recombinase (data not
shown). Time course analysis of SPARC expression showed
that the maximal suppression of SPARC secretion was
observed between days 4 and 5 (Figure 1b). Similarly,
maximal SPARC secretion was observed at day 4 (Figure
1b). At day 15, SPARC levels returned to basal levels (Figure
1b). A day 4 loading control of total protein was also included
(Figure 1c). Hyperexpression of SPARC in melanoma cells
resulted only in a nonsignificant growth inhibitory effect in
the two melanoma cell lines, whereas its downregulation had
essentially no effect (Figure 1d and e).
Positive and negative modulation of SPARC levels inhibits and
enhances, respectively, melanoma spheroid growth
To assess the role of SPARC produced by the different cell
components of a tumor mass, we performed in vitro assays
using spheroids made of melanoma cells alone or combined
with fibroblasts. SPARC hyperexpression in A375N cells
(A375N-SP) had a profound inhibitory effect on spheroid
growth that was increasingly evident with time (Figure 2a).
On the contrary, downregulation of SPARC expression in
melanoma cells (A375N-SPas) induced a statistically sig-
nificant increase in spheroid growth capacity compared to
Ad-bgal-transduced cells (Figure 2a). Interestingly, cells
transduced with Ad-bgal (A375N-bgal) also exhibited re-
duced growth capacity at the earliest time points, probably
due to the increase in SPARC levels induced by Ad-bgal
transduction (Figure 2a). Western blot analysis shows that
increased SPARC production by spheroids made of A375N-SP
lasted for at least 10 days compared to the other groups
(Figure 2b). On the other hand, spheroids made of A375N-
SPas cells showed 20–25% reduced secretion of SPARC
throughout the experiment, which is probably an under-
estimation of the reduction in SPARC secreted levels (Figure
2b). A375N-bgal and A375N-SPas spheroids showed a
closely packed inner core surrounded by an outer layer of
more loosely associated cell aggregate and neat borders
(Figure 2c and d). On the contrary, A375N-SP spheroids were
essentially devoid of the external layer, which was comple-
tely disassembled after 4 days of incubation (Figure 2e). Very
similar results were obtained with IIB-Mel-J cells (data not
shown). As a whole, these data indicate that SPARC
hyperexpression in melanoma cells inhibits spheroid growth,
whereas downregulation of SPARC expression showed the
opposite effect, enhancing spheroid growth capacity.
www.jidonline.org 2619
F Prada et al.
Stroma-Derived SPARC and Melanoma Growth
SPARC overexpression by neighboring fibroblasts does not alter
the growing rate of heterotypic melanoma spheroids
We next evaluated whether melanoma spheroid growth
might be affected by the presence of neighboring fibroblasts.
Heterotypic spheroids made of A375N-SPas and WI-38 cells
showed an enhanced growth, although not statistically
significant (P40.05), whereas heterotypic spheroids made
of A375N-SP and WI-38 cells were completely growth
inhibited (Figure 3a).
Next, we assessed whether changes in the expression
levels of SPARC in neighboring WI-38 cells might affect
heterotypic spheroid growth. For this purpose, we transduced
WI-38 cells, which express low levels of SPARC that are not
detected in Western blots unless 10-fold concentrated
medium is loaded (data not shown), with Ad-SP (WI38-SP).
WI38-SP cells showed strong SPARC expression, similar to
the levels produced by A375N-SP cells (Figure 3b). Figure 3
shows that spheroid growth was not affected by SPARC levels
secreted by neighboring fibroblasts, because no difference
was found in heterotypic spheroid growth regardless of
whether WI-38 cells overexpressed SPARC (Figure 3c).
Because the endogenous levels of SPARC produced by
melanoma cells could be sufficient to attain its maximal
effect, we prepared spheroids made of WI38-SP mixed with
A375N-SPas cells instead of native A375N melanoma cells.
Even in this case, when SPARC levels produced by A375N-
SPas cells were only 10–15% of the amount produced by
native A375N cells, spheroid growth was not affected
by the levels of SPARC produced by neighboring fibroblasts
(Figure 3d). It can be concluded as a whole that heterotypic
spheroid growth was affected only by the amount of SPARC
secreted by the melanoma cells themselves, whereas SPARC
produced by neighboring fibroblasts had no effect on
spheroid growth.
Viral dose
a
b
c
d
e
Mock 1×108 5×108 1×108 5×108
Ad-SPas
Mel J-SPas
3.5
3.0
2.0
1.0
2.5
1.5
0.5
2.0
1.0
2.5
1.5
0.5
10
4  
ce
lls
/w
e
ll
10
4  
ce
lls
/w
e
ll
0 20 40 60 80
Hours
100 120
0 20 40 60 80
Hours
100 120
Mel J-SP
Ad-SPas
Ad-SPas
Ad-SP
Ad-SP
Ad-gal
Ad-gal
Ad-gal
TCID50/ml
IIB-Mel-J
A375N
IIB-Mel-J
IIB-Mel-J
Mel J-gal
A375N-SPas
A375N-SP
A375N-gal
Days
100
100
42
2
4
5
10
15
16
15
90
91 94
162
328
437
222100
100
100
100
100
278 343 93
161 159 149 36
27
Figure 1. Modulation of SPARC levels in melanoma cells does not greatly impair their in vitro growth. (a) Western blot of conditioned media obtained from
IIB-Mel-J and A375N melanoma cells following transduction with the different adenoviral vectors. Samples were collected at day 4 after cell transduction.
(b) Time course of SPARC secretion by IIB-Mel-J cells transduced with the various adenoviral vectors. (c) Loading control of total protein at day 4.
(d) In vitro growth of IIB-Mel-J cells transduced with the different adenoviral vectors. (e) In vitro growth of A375N cells transduced with the different
adenoviral vectors. Data are expressed as means7SD. An adenoviral TCID50/ml of 5 108 was used in b, c, d, and e.
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Host polymorphonuclear cells are responsible for the rejection
of human melanoma cells expressing reduced SPARC levels
The next experiments aimed to establish whether changes in
SPARC levels produced by melanoma cells or by neighboring
stromal cells might affect the in vivo growth capacity of
melanoma cells. Confirming previous studies (Alvarez et al.,
2005), the in vivo growth capacity of melanoma cells
expressing reduced SPARC levels (Mel J-SPas) was strongly
inhibited in nude mice compared to control Mel J-bgal or
mock-transduced melanoma cells (Figure 4a). Interestingly,
more than 50% of mice injected with Mel J-SPas survived
after 100 days, compared to none in the other two groups
(Figure 4b). Similar effects were observed with A375N cells
(Alvarez et al., 2005, and data not shown). Confirming
previous results (Alvarez et al., 2005), tumor growth
inhibition was accompanied by a fourfold increase in the
amount of intratumoral recruited polymorphonuclear cells
(PMN; data not shown). Because previous studies suggested
that host PMN might be responsible for the rejection of
malignant cells, we depleted PMN by using specific
neutralizing antibodies. Initial experiments showed that
anti-Gr-1 antibody administration (RB6-8C5 clone) depleted
host PMN for at least 15 days (data not shown). Administra-
tion of anti-PMN antibodies completely reverted the inhibi-
tion of melanoma growth induced by downregulation of
SPARC expression, indicating that host PMN were respon-
sible for melanoma rejection (Figure 4c). Interestingly,
depletion of host PMN also accelerated the in vivo growth
of non-genetically modified IIB-Mel-J cells, highlighting a
general role of host PMN in controlling human melanoma
xenograft growth (Figure 4c).
SPARC hyperexpression by melanoma cells promotes stroma
reorganization without affecting their in vivo tumor growth
Our previous data demonstrated that melanoma spheroid
growth was greatly inhibited following SPARC overexpres-
sion. To establish whether SPARC hyperexpression might also
affect the in vivo growth of melanoma cells, we xenotrans-
planted nude mice with melanoma cells transduced ex vivo
with Ad-SP. In contrast to the results obtained with spheroids,
SPARC hyperexpression in A375N cells did not alter their
in vivo growth at all compared to control cells transduced
ex vivo with Ad-bgal (Figure 4d). Similar results were
obtained with IIB-Mel-J cells (Figure 4e).
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Figure 2. Modulation of SPARC levels in melanoma cells affects their growth as spheroids. (a) Growth rate of spheroids made of A375N cells transduced
with 5 108 TCID50/ml of the different vectors. Data are expressed as means7SD of at least seven spheroids and three different experiments (**Po0.01).
(b) Conditioned media obtained from spheroids at the indicated time points were used to assess SPARC secretion. Loading control of total protein was included.
(c–e) A375N spheroid morphology at day 4. Bar¼ 150 mm.
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Interestingly, however, clear differences were observed when
immunohistological studies were performed. Mel J-SP tumors
hyperexpressed SPARC in vivo for at least the first 5 days
compared to control cells transduced with Ad-bgal (Figure 5a
and b). SPARC hyperexpression by melanoma cells was also
accompanied by an increased amount of fibroblasts that were
mainly located in a collagen-rich tumor area (Figure 5c).
Indeed, Masson’s trichrome staining revealed a twofold
increase in collagen deposition in melanoma tumors over-
expressing SPARC compared to control tumors (Figure 5f).
This collagen was observed at the tumor interface between
the malignant nests and the surrounding host tissue (compare
Figure 5d and e). On the other hand, we observed no
differences in the amount of the recruited inflammatory
infiltrate following SPARC hyperexpression (data not shown).
Immunohistochemical analysis using an anti-CD31 antibody
revealed increased angiogenesis, as peritumoral microvessel
density was significantly augmented in melanoma tumors
hyperexpressing SPARC compared to the control (Figure 5g
and h). This difference was clearly evidenced at day 5 after
cell administration (Figure 5i). Interestingly, autopsies of the
mice at 40 days revealed no differences, neither in the
amount of vessels nor in fibroblast recruitment or collagen
deposition, between melanomas obtained from cells that
hyperexpressed SPARC and control melanomas (data not
shown). Finally, no difference in the in vivo proliferation rate
was observed as assessed with an anti-Ki-67 antibody (data
not shown). Thus, all the evidence indicates that the
remarkable changes in stroma composition observed in
tumors transiently hyperexpressing SPARC did not affect
melanoma growth.
Coadministration of fibroblasts overexpressing SPARC or not
has no effect on melanoma outcome
In the previous studies it could be argued that human
melanoma cells could have been unable to establish proper
interactions with murine stroma. Therefore, we co-injected
melanoma cells with human fibroblasts and followed their in
vivo growth capacity in nude mice. We initially transduced
IIB-Mel-J cells ex vivo with Ad-SP and co-injected them into
nude mice with an equivalent amount of WI-38 cells.
Coadministration of WI-38 cells had no effect on the in vivo
growth capacity of Mel J-SP cells compared to control Mel J-
bgal cells coadministered with WI-38 cells (Figure 6a). In
concordance with the spheroid data, overexpression of
SPARC in coadministered WI-38 cells also had no effect on
the in vivo growth of unmodified IIB-Mel-J cells (Figure 6b).
To establish whether coadministration of transformed fibro-
blasts might have a different effect, we co-injected IIB-Mel-J
cells with WI-38 VA fibroblasts, a transformed variant stably
expressing the SV40 large T antigen, which were transduced
ex vivo with Ad-SP. Figure 6 shows no effect of SPARC
overexpression in coadministered WI-38 VA fibroblasts on
melanoma growth outcome (Figure 6c). This set of experi-
ments indicates as a whole that SPARC overexpression in
fibroblasts had no effect on melanoma growth.
DISCUSSION
Here, we show that the in vitro and in vivo growth capacity of
human melanoma cells depends essentially on SPARC levels
produced by the malignant cells themselves, whereas SPARC
produced by stromal cells has no apparent role on melanoma
growth. Indeed, manipulation of SPARC levels in neighboring
human fibroblasts in heterotypic spheroids or in vivo did not
affect melanoma cell growth. Moreover, changes in stroma
organization induced by SPARC did not substantially affect
melanoma growth.
Despite the contradictory results on tumor growth that we
have extensively presented in the introduction, it was
proposed that the main role of host-derived SPARC in cancer
progression is in the appropriate organization of the ECM
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(Brekken et al., 2003). It was proposed that the stroma may
act as a shield to protect tumors from the immune infiltrate;
thus, a less-dense stroma such as the one observed in SPARC-
null mice may allow recruitment of immune infiltrate and
hence tumor rejection (Sangaletti et al., 2003). Alternatively,
the less-dense stroma in SPARC-null mice also showed a
reduced blood vessel number, suggesting that a smaller blood
supply might have also affected tumor growth (Sangaletti
et al., 2003). The discrepancy regarding tumor growth was
suggested to be based on the different interactions that tumor
cells establish with the surrounding stroma; certain tumor
cells might favor proteolysis of stromal proteins leading to
angiogenesis inhibition, whereas other cell types might
induce the opposite, thus inhibiting or promoting tumor
growth (Sangaletti et al., 2003; Chlenski et al., 2006).
On the basis of previous discrepancy, we attempted to
establish the ECM role in melanoma growth by initially
modulating SPARC levels in melanoma cells and monitoring
tumor growth and ECM organization. We conclude that the
increases in angiogenesis, collagen deposition, and fibroblast
recruitment induced by SPARC hyperexpression in melano-
ma cells have no significant effect on melanoma outcome,
clearly indicating that melanoma growth is essentially not
affected by the composition or organization of the neighbor-
ing stroma. It is of note that stromal reorganization was
observed at the initial stages of melanoma growth, when
transient adenoviral-directed hyperexpression of SPARC was
higher. In fact, necropsy of the mice at 40 days revealed no
differences in ECM organization between control and SPARC-
hyperexpressing melanomas. Whether sustained SPARC
overexpression in melanoma cells and concomitant remodel-
ing of ECM might result in increased melanoma growth
in vivo remains to be tested. However, in initial studies,
we observed that stable hyperexpression of SPARC in
melanoma cells resulted in a nonsignificant inhibition of in
vivo tumor growth, supporting the data obtained in the
present studies (Viale et al., manuscript in preparation).
Moreover, the fact that tumor cell rejection occurs during the
first 72 hours suggests that 10 days of SPARC hyperexpression
must suffice for the protein to exert an effect on tumor
growth. Because human melanoma cells might also be
disadvantageous in the generation of proper interactions with
rodent stromal cells, we modulated SPARC levels in
coadministered human fibroblasts. We conclude that the
presence or absence of neighbor human fibroblasts expres-
sing or not expressing SPARC has no effect on melanoma
growth, strengthening the fact that the changes in surround-
ing stroma induced by SPARC have no profound influence on
melanoma outcome. The question as to whether the amount
and biochemical characteristics of SPARC produced by
neighboring fibroblasts might define its potential paracrine
effect is currently under investigation.
It was of note that SPARC overexpression almost
obliterated melanoma cell growth as spheroids, whereas
SPARC downregulation increased spheroid growth. Because
SPARC hyperexpression had little or no effect at all when
cells were grown in vitro as monolayers or in vivo, it is
tempting to speculate that SPARC might have affected the
anchorage-independent growth capacity of melanoma cells.
In addition, we observed a reduced clonogenic capacity of
melanoma cells grown in semisolid agar following over-
expression of SPARC (data not shown). No previous evidence
was presented for the potential role of SPARC on anchorage-
independent growth of tumor cells. Recent studies using cells
obtained from SPARC-null mice indicated that SPARC might
regulate the cell cycle through the concurrently induced
expression of p107 and cyclin A (Basu et al., 1999). Cyclin A
has been shown to be a direct target of c-Jun and to be
necessary for c-Jun-induced anchorage-independent growth
of certain cancer cells (Katabami et al., 2005). Interestingly,
SPARC expression has been shown to be both upregulated
and downregulated in response to c-Jun overexpression
(Kraemer et al., 1999; Vial et al., 2000; Briggs et al.,
2002;). Overall these data suggest a potential link between
SPARC, cyclin A, Jun, and anchorage-independent growth of
tumor cells. It might be hypothesized that the timely
regulation of SPARC levels might allow melanoma cells to
grow in an anchorage-independent way favoring metastatic
dissemination.
The role of SPARC in angiogenesis is a matter of
controversy. Several studies have shown that SPARC might
impair angiogenesis through the inhibition of the vascular
endothelial growth factor mitogenic effect on endothelial
cells, which in some cases inhibited tumor growth (Kupprion
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Figure 6. Coadministration of fibroblasts overexpressing SPARC or not has no effect on melanoma cell growth. (a) WI-38 fibroblasts mixed either with
Mel J-bgal or with Mel J-SP were co-injected into nude mice. (b) IIB-Mel-J cells mixed either with WI38-bgal or with WI38-SP cells were co-injected into nude
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et al., 1998; Said and Motamed, 2005; Chlenski et al., 2006;
Nozaki et al., 2006), whereas others have shown that
vascular endothelial growth factor might upregulate SPARC
levels produced by endothelial cells (Kato et al., 2001) and
that SPARC by itself might promote angiogenesis (Brekken
et al., 2003). This data indicate that SPARC hyperexpression
promotes angiogenesis in melanoma tumors as assessed by
the increased number of microvessels stained with an anti-
CD31 antibody. Recent studies demonstrated that SPARC
cleavage by MMPs released fragments that stimulated or
inhibited proliferation and migration of endothelial cells in
mutually exclusive manners (Sage et al., 2003). Moreover,
SPARC has been shown to modulate MMP expression in
melanoma cells (Ledda et al., 1997a). Thus, the evidence
indicates that the role of SPARC in angiogenesis is dependent
on the tumor cell type and the availability of concurrent
factors such as MMPs that might also influence the same
process.
Here we show that depletion of host PMN by specific
antibodies is sufficient to completely revert melanoma
rejection, thereby providing definitive evidence on the
central role of host PMN in this process. The role of host
PMN in tumor promotion or rejection is still under discus-
sion. Various studies have shown that PMN are responsible
for rejection of tumor cells ectopically expressing cytokines
such as G-CSF, IL-2, or Fas L (Alvarez et al., 2005; Motomu
Shimizu et al., 2005; Stoppacciaro et al., 1994). On the other
hand, others have also shown that PMN were required for
acquisition of a metastatic phenotype of benign murine
fibrosarcoma cells (Tazawa et al., 2003). Also, PMN
depletion in nude mice by using the RB6-8C5 antibody
inhibited growth of tumors induced by UV light (Pekarek
et al., 1995). It appears plausible, then, that PMN might play
a different role in different tumor types or they might behave
differently at different stages of tumor growth.
In conclusion, these studies show that SPARC levels
produced only by the melanoma cells themselves affect
tumor growth, whereas these malignant cells are essentially
resistant to external SPARC influence as assessed both in vitro
and in vivo. Although the precise role of the stroma in
melanoma growth is still elusive, we speculate that it might
become crucial only at certain stages of melanoma develop-
ment.
MATERIALS AND METHODS
Cells and cell cultures
A375N human melanoma cells were grown in melanoma medium
(DMEM/F12, 3.6 g/l HEPES, 1.5 g/l NaHCO3, 5 mg/l insulin, 17.6 mg/l
ascorbic acid, and 0.3 g/l galactose). IIB-Mel-J melanoma cells were
grown in melanoma medium supplemented with 5 mg/l epidermal
growth factor, 500mg/l transferrin, and 0.92 g/l NaHCO3. Human
embryonic fibroblasts (WI-38 and WI-38 VA-13) were grown in
DMEM supplemented with MEM nonessential amino acids. All
complete media were supplemented with 10% v/v fetal bovine
serum and antibiotics. Cell cultures were maintained at 371C in a 5%
CO2 humidified incubator. Cell culture reagents were from Gibco
(Invitrogen, Grand Island, NY).
Construction of adenoviral vectors and cell transduction
The adenoviral vectors carrying human SPARC sense (Ad-SP) and
antisense (Ad-SPas) were prepared using the full-length human
SPARC cDNA (Podhajcer et al., 1996). A 1.7 kb SalI fragment
containing the cDNA was released from pBluescript SKþ and
cloned into the SalI site of the shuttle vector pADPSY-LTRSVpolyA.
To obtain the recombinant adenoviruses, each of the shuttle vectors
containing the SPARC cDNA in both orientations was cotransfected
into human embryonic kidney 293 cells with the large ClaI fragment
(2.6–100 mu) of Ad5 DNA lacking the E3 regions (Lieber et al.,
1996). Viral stock titers were determined by optic density and
TCID50 (Reed, 1938). An additional adenoviral vector, containing
527 bp of Escherichia coli b-galactosidase coding sequence, was
prepared following the same protocol (Ad-bgal). All viral stocks
contained o12.5 endotoxin units/ml as assessed using the E-Toxate
kit (Sigma Co., St Louis, MO).
For cell transduction, cells were grown up to 80% confluence in
monolayer and transduced with 5 108 TCID50/ml of the different
adenoviral vectors for 6 hours. At the end, the transduction medium
was replaced with fresh complete medium; cells were incubated for
an additional 20 hours, trypsinized, counted, and used. Transduction
efficiency was assessed 36 hours after transduction with Ad-bgal
followed by X-gal (Alam and Cook, 1990). Experiments were run
only when transduction efficiency was better than 60 and 75% for
IIB-Mel-J and A375N cells, respectively.
Production of monoclonal antibodies and Western blot analysis
Monoclonal antibodies recognizing human SPARC were obtained by
intrasplenic immunization of BALB/c mice with 200 mg of human
rSPARC in 50 ml of phosphate-buffered saline (PBS) (Wayne et al.,
2006). Positive clones were mostly of the IgMk and IgMl isotypes
(IsoStrip; Roche Molecular Biochemicals, Indianapolis, IN). Anti-
SPARC (IgMk) 7A5 monoclonal antibody was purified from an
ascitic fluid by using Sephacryl S-400 (GE Healthcare, Uppsala,
Sweden). To obtain conditioned media, nearly confluent cells were
washed twice with PBS and kept in serum-free medium. After
24 hours, the medium was collected, supplemented with 1 mM
phenylmethylsulfonyl fluoride, and quantified using a NanoOrange
Protein Quantitation Kit (Molecular Probes, Eugene, OR). One
microgram of protein was separated in SDS-PAGE under reducing
conditions and transferred onto nitrocellulose membranes (Schlei-
cher & Schuell Bioscience, London, UK). Loading controls were
performed to validate protein quantification using Sypro Ruby
protein gel stain (Sigma). After being blocked with skimmed milk
in PBS, membranes were incubated with mAb-7A5 overnight at 41C.
After being washed with 0.05% Tween-20 in PBS, membranes were
further incubated for 2 hours at room temperature with horseradish
peroxidase-conjugated goat anti-mouse antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA). Bands were detected using the
ECL Plus Western Blotting Detection System (GE Healthcare,
Buckinghamshire, UK). SPARC levels were quantified by densit-
ometer analysis using the ImageJ 1.33u software (National Institutes
of Health, Bethesda, MD).
Proliferation assays
Cell proliferation was measured using the colorimetric MTT assay
(Sigma). Briefly, 3 103 cells/well were seeded onto a 96-well plate
in a final volume of 100 ml per well. At each time point, 10 ml of
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5 mg/ml 3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyl tetrazolium bro-
mide was added to each cell culture plate. Two hours later, the
formazan dye was solubilized and read at 550 nm optical density as
described (Denizot and Lang, 1986).
Three-dimensional spheroids
Ninety-six-well tissue culture plates were coated with 75ml of 1%
agarose in PBS. Nearly confluent cells were washed twice with PBS,
trypsinized, and seeded at 104 cells/well in 150ml of melanoma
medium for melanoma cells and DMEM for fibroblasts to obtain a
single homotypic spheroid per well. Heterotypic spheroids were
built using 5 103 each of A375N and WI-38 cells grown in a mix of
melanoma medium and DMEM. Seventy-five microliters of super-
natant was carefully removed from each well every 3 days and
replaced with fresh medium. Spheroid size was measured every 2
days using an inverted microscope containing a  10 eyepiece ruler
graduated to 0.01 mm. Spheroid volume was determined using the
equation V¼ (LW2) 0.5, where L is length and W is width of the
spheroid. Spheroid conditioned media were obtained by pooling five
spheroids followed by three washes with PBS and incubation in the
absence of serum for 24 hours.
In vivo tumor growth
For assessment of the in vivo tumor growth, A375N and IIB-Mel-J
human melanoma and WI-38 fibroblast cell lines were transduced
ex vivo with Ad-SP, Ad-SPas, and Ad-bgal. Twenty hours later cells
were trypsinized, counted, and resuspended in 100 ml of PBS. Six- to
8-week-old male athymic N:NIH(S)-nu mice were subcutaneously
injected into the left flank with 5 106 IIB-Mel-J or 3 106 A375N
melanoma cells or a mix of 5 106 IIB-Mel-J and 4 106 fibroblasts.
Perpendicular diameters were used to determine tumor volume, as
V¼ d s2 dl/2, where ds is the smaller diameter and dl is the larger
one. All in vivo experiments followed institutional guidelines
approved by NIH authorities.
Depletion of PMCs
Conditioned medium containing anti-Gr-1 antibody was prepared
from RB6-8C5 hybridoma clone (Dr. Coffman, DNAX Research
Institute, Palo Alto, CA), whereas the anti-CD4 antibody was
prepared from a GK1.5 hybridoma clone (TIB 207TM, ATCC,
Manassas, VA). For PMN depletion, mice were intraperitoneally
injected every 2 days starting 2 days before tumor inoculation with
the specific RB6-8C5 antibody. To quantify the effect of RB6-8C5 on
PMN depletion, we induced PMN mobilization by injecting casein
and then recovered PMN from the abdominal cavity (Luo and
Martin, 2006). Briefly, animals were injected twice (18 and 3 hours
before they were killed) intraperitoneally with 1 ml of 4% casein in
PBS. The cellular suspension obtained from the peritoneal exudates
was centrifuged 10 minutes at 1000 r.p.m. and the relative amount of
PMN was assessed by differential counting using May Grunwald-
Giemsa staining of the smear.
Histology and immunohistochemistry
Eight-micrometer-thick tumor sections were deparaffinized in xylene
and rehydrated in graded ethanol. For antigen unmasking, sections
were immersed in citrate buffer (pH¼ 6) and boiled twice in a
microwave oven. Endogenous peroxidase activity was blocked by
soaking the sections in 3% hydrogen peroxide in methanol for
15 minutes. Nonspecific binding sites were blocked by incubating
the sections in normal goat serum (10% in PBS). Excess serum was
then removed and the tissue sections were incubated overnight with
anti-hSPARC rabbit polyclonal antibody (Ledda et al., 1997b) at
1/200 dilution. After the slides were washed twice in PBS for
10 minutes, the sections were incubated with biotinylated goat anti-
rabbit antibody (Vector Laboratories, Burlingame, CA) at 1/400
dilution for 45 minutes, followed by a PBS wash. The sections were
subsequently incubated with Vectastain ABC reagent (Vector
Laboratories, Burlingame, CA) for 45 minutes. Color was developed
by incubating the sections with liquid diaminobenzidine (substrate
chromogen system, DakoCytomation, Carpinteria, CA). Finally, the
sections were counterstained with hematoxylin, dehydrated, and
mounted.
For total collagen detection, deparaffinized sections were stained
with Masson’s trichrome according to standard protocols. Collagen
content was quantitatively determined using the Image-Pro Plus
software (Media Cybernetics, Silver Springs, MD). Briefly, five areas
from serial sections of tumor explants obtained from at least four
different animals were digitally selected. The collagen-rich area of
each selected field was measured using the ‘‘area measurement’’
within the ‘‘count tool’’ belonging to the Image-Pro Plus software.
Fibroblasts were counted by our pathologist (AIB) under a light
microscope.
For CD31 detection, tumors were fixed in 4% paraformaldehyde
for 1 hour, cryopreserved overnight in 30% sucrose, embedded in
tissue OCT, and stored at 201C. Cryostat sections of 9mm were
mounted on gelatin-coated slides and rehydrated in graded ethanol.
For antigen retrieval, a 3 minute pepsin digest was performed. Slides
were incubated overnight with anti-CD31 (PharMingen, San Diego,
CA) at a 1/600 dilution. After being washed, the sections were
incubated with 1/400 dilution of biotinylated goat anti-rat antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA). Product
visualization was performed as described above. Slides were
counterstained with hematoxylin. PBS was used instead of the first
antibody as a control. After the immunostaining, the entire tumor
section was scanned at low power ( 40) to identify areas of
neovascularization. Individual or small-caliber microvessels were
then counted under high power ( 400) to obtain a vessel count in a
defined area. Data were obtained from three animals at each time
point. We analyzed five areas of each sample.
Statistical analysis
Survival rates were calculated with the Kaplan–Meier method and
their differences were evaluated by the log-rank test. Statistical
difference between groups was determined by one-way analysis of
variance follow by a Dunnett’s multiple comparison test. A P-value
of o0.05 was considered statistically significant. Data analysis was
performed with the Prism GraphPad (GraphPad Software, Inc.,
San Diego, CA).
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